AI assistant
DEXCOM INC — Director's Dealing 2024
Mar 11, 2024
30198_dirs_2024-03-11_fdee11be-2f03-4c30-bb2f-2d8a4e292093.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2024-03-08
Reporting Person: SAYER KEVIN R (Director, President CEO and Chairman)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-08 | Common Stock | A | 51692 | $0.0 | Acquired | 414533 | Direct |
Footnotes
F1: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
F2: Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025.